JESSICA AZEVEDO WATERMAN

Mrs. JESSICA AZEVEDO WATERMAN


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
JWJESSICA AZEVEDO WATERMAN
JESSICA AZEVEDO WATERMAN
PNPaloma Napoleão-Pêgo
Paloma Napoleão-Pêgo
DHDiogo N. Harriz
Diogo N. Harriz
JCJoao P. R. S. Carvalho
Joao P. R. S. Carvalho
MFMariana S. Freitas
Mariana S. Freitas
Salvatore Giovanni De-SimoneSalvatore Giovanni De-Simone
Salvatore Giovanni De-Simone
Background: Malaria remains a major global public health problem, causing millions of cases and thousands of deaths each year. Without an effective antimalarial vaccine, diagnosis remains a key strategy for disease control. However, false-negative results due to the emergence of P. falciparum populations with deletions in the Pfhrp2/3 genes may compromise case management. Thus, this study aimed to identify and characterize linear B-cell epitopes of the MSP9 protein to evaluate new targets for developing high-precision biotechnological tools for malaria diagnosis. Methods: We mapped MSP9 epitopes using a peptide microarray strategy, followed by epitope screening with bioinformatics tools and ELISA validation. Results: We identified 31 MSP9 epitopes through SPOT synthesis, 16 of which were in regions exhibiting low structural or chemical similarity to homologous proteins from other Plasmodium species. ELISA analysis revealed that the peptides PfMSP9/IgG/23, PfMSP9/IgG/27, and PfMSP9/IgG/30 exhibited sensitivities of 44.81%, 87.23%, and 46.81%, and specificities of 81.82%, 95.74%, and 89.74%, respectively. Conclusions: Our findings indicate that the PfMSP9/IgG/27 peptide, owing to its high sensitivity and specificity, enabled the differentiation of individuals infected with P. falciparum from those infected with P. vivax. Despite the low sensitivity of the other peptides, their high specificity allowed us to differentiate between the two organisms. We believe that using additional MSP9 epitopes and applying the same approach to other P. falciparum proteins will make it possible to develop a chimeric antigen for serological diagnosis of malaria.